Universitätsklinikum Essen

Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole: Final results (2021) Reinisch M, Nusch A, Decker T, Hartkopf A, Heinrich BJ, Kurbacher CM, Fuchs R, et al. Conference contribution Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study (2021) Wockel A, Brucker C, Decker T, Falbrede J, Forstbauer H, Gohler T, Hoffmann O, et al. Conference contribution Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial (2021) Fehm T, Mueller V, Banys-Paluchowski M, Fasching P, Friedl TWP, Hartkopf A, Huober J, et al. Conference contribution Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program (2021) Muller V, Banys-Paluchowski M, Friedl TWP, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, et al. Journal article Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era (2021) Rodriguez-Freixinos V, Capdevila J, Pavel ME, Thawer A, Baudin E, O'Toole D, Herrmann K, et al. Journal article, Review article Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) Rogiers A, Da Silva IP, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, et al. Journal article [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma (2021) Harder FN, Jungmann F, Kaissis GA, Lohoefer FK, Ziegelmayer S, Havel D, Quante M, et al. Journal article Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. (2021) Carpinteiro A, Gripp B, Hoffmann M, Poehlmann S, Hoertel N, Edwards MJ, Kamler M, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article